
Antoine Hollebecque

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8555199/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. New England Journal of Medicine, 2015, 373, 726-736.	13.9	1,483
2	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clinical Cancer Research, 2017, 23, 1920-1928.	3.2	960
3	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2020, 21, 671-684.	5.1	923
4	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncology, The, 2018, 19, 1180-1191.	5.1	811
5	The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology, 2007, 45, 1348-1354.	3.6	598
6	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discovery, 2017, 7, 586-595.	7.7	554
7	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer. Cancer Discovery, 2018, 8, 428-443.	7.7	448
8	Prospective Study of the Long-Term Effects of Bariatric Surgery on Liver Injury in Patients Without Advanced Disease. Gastroenterology, 2009, 137, 532-540.	0.6	440
9	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. JAMA Oncology, 2019, 5, 546.	3.4	366
10	Infection in Patients With Severe Alcoholic Hepatitis Treated With Steroids: Early Response to Therapy Is the Key Factor. Gastroenterology, 2009, 137, 541-548.	0.6	305
11	BRAF Inhibition in <i>BRAF</i> ^{V600} -Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36, 3477-3484.	0.8	247
12	Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Annals of the Rheumatic Diseases, 2017, 76, 1747-1750.	0.5	200
13	Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors. Journal of Clinical Oncology, 2014, 32, 68-75.	0.8	179
14	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1696-1707.	7.7	157
15	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. Clinical Cancer Research, 2014, 20, 246-252.	3.2	144
16	Clinicogenomic Analysis of <i>FGFR2</i> -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. Cancer Discovery, 2021, 11, 326-339.	7.7	144
17	Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF). Medicine (United) Tj ETQq1 1	0.784314 0.4	rgBT/Overic

18 The Evolution of Severe Steatosis After Bariatric Surgery Is Related to Insulin Resistance. Gastroenterology, 2006, 130, 1617-1624.

0.6 136

#	Article	IF	CITATIONS
19	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). European Journal of Cancer, 2017, 84, 212-218.	1.3	132
20	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. European Journal of Cancer, 2017, 87, 122-130.	1.3	120
21	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clinical Cancer Research, 2020, 26, 242-255.	3.2	114
22	A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology, 2016, 27, 2268-2274.	0.6	108
23	Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). Cancer Research, 2017, 77, CT074-CT074.	0.4	106
24	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and Toxicity. PLoS ONE, 2013, 8, e77472.	1.1	104
25	Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. Clinical Cancer Research, 2016, 22, 2960-2968.	3.2	103
26	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nature Cancer, 2020, 1, 965-975.	5.7	98
27	Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research, 2019, 25, 946-956.	3.2	96
28	An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers Journal of Clinical Oncology, 2017, 35, 5504-5504.	0.8	89
29	Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. Clinical Cancer Research, 2020, 26, 764-774.	3.2	85
30	Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. European Journal of Gastroenterology and Hepatology, 2011, 23, 499-506.	0.8	82
31	Systemic treatment of pancreatic cancer revisited. Seminars in Oncology, 2019, 46, 28-38.	0.8	81
32	Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Molecular Oncology, 2016, 10, 566-574.	2.1	74
33	Molecular targeted therapy of <i>BRAF</i> -mutant colorectal cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985649.	1.4	72
34	Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts Journal of Clinical Oncology, 2017, 35, 4015-4015.	0.8	71
35	Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer, 2015, 51, 327-339.	1.3	63
36	Low skeletal muscle is associated with toxicity in patients included in phase I trials. Investigational New Drugs, 2014, 32, 382-387.	1.2	60

#	Article	IF	CITATIONS
37	A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Molecular Cancer Therapeutics, 2020, 19, 460-467.	1.9	60
38	Targeted therapy-induced radiation recall. European Journal of Cancer, 2013, 49, 1662-1668.	1.3	55
39	Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. European Journal of Cancer, 2018, 101, 160-164.	1.3	52
40	Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Annals of Oncology, 2018, 29, 1304-1311.	0.6	51
41	Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France. Journal of Hepatology, 2008, 49, 175-183.	1.8	46
42	A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 1229-1236.	3.2	43
43	Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: A prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. European Journal of Cancer, 2013, 49, 431-438.	1.3	41
44	<i>BRAF</i> -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research, 2020, 26, 2466-2476.	3.2	39
45	Vascular disrupting agents. Current Opinion in Oncology, 2012, 24, 305-315.	1.1	37
46	Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). European Journal of Cancer, 2016, 59, 79-89.	1.3	36
47	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Scientific Reports, 2019, 9, 11610.	1.6	36
48	A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. European Journal of Cancer, 2017, 87, 131-139.	1.3	35
49	Neutrophil Migration During Liver Injury Is Under Nucleotide-Binding Oligomerization Domain 1 Control. Gastroenterology, 2010, 138, 1546-1556.e5.	0.6	32
50	Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2019, 3, 1-9.	1.5	31
51	Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. European Journal of Cancer, 2013, 49, 2791-2797.	1.3	29
52	A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. European Journal of Cancer, 2014, 50, 876-884.	1.3	29
53	Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpointÂblockers (PD-1/PD-L1 inhibitors). European Journal of Cancer, 2017, 84, 202-211.	1.3	29
54	Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors. Clinical Cancer Research, 2021, 27, 6393-6404.	3.2	29

#	Article	IF	CITATIONS
55	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase–mutated intrahepatic cholangiocarcinomas. European Journal of Cancer, 2018, 90, 83-91.	1.3	28
56	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer Discovery, 2022, 12, 1435-1448.	7.7	28
57	Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?. European Journal of Cancer, 2017, 81, 161-173.	1.3	27
58	Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase. Annals of Oncology, 2015, 26, 1005-1011.	0.6	25
59	A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clinical Cancer Research, 2015, 21, 5235-5244.	3.2	25
60	Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2017, 79, 1257-1265.	1.1	25
61	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. Annals of Surgical Oncology, 2017, 24, 3640-3646.	0.7	25
62	An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) Journal of Clinical Oncology, 2017, 35, 6025-6025.	0.8	25
63	First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. European Journal of Cancer, 2017, 81, 142-150.	1.3	24
64	A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma. Investigational New Drugs, 2013, 31, 1530-1538.	1.2	22
65	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Medicine, 2020, 9, 2643-2652.	1.3	21
66	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Cancer Research, 2021, 27, 438-446.	3.2	21
67	First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3556-3566.	3.2	21
68	Patient-reported tolerability of adverse events in phase 1 trials. ESMO Open, 2017, 2, e000148.	2.0	20
69	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> ^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	1.5	20
70	Dysphonia induced by anti-angiogenic compounds. Investigational New Drugs, 2014, 32, 774-782.	1.2	19
71	Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i> -mutant ganglioglioma. Neurology, 2018, 91, 523-525.	1.5	19
72	Immunotherapy in Advanced Biliary Tract Cancers. Cancers, 2021, 13, 1569.	1.7	19

#	Article	IF	CITATIONS
73	Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. British Journal of Cancer, 2015, 113, 1413-1420.	2.9	18
74	Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?. European Journal of Cancer, 2018, 103, 108-119.	1.3	18
75	Tumor Assessment Criteria in Phase I Trials: Beyond RECIST. Journal of Clinical Oncology, 2013, 31, 395-395.	0.8	17
76	Implementing precision medicine initiatives in the clinic. Current Opinion in Oncology, 2014, 26, 340-346.	1.1	17
77	Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemotherapy and Pharmacology, 2014, 73, 1189-1196.	1.1	17
78	Bevacizumab-induced laryngeal necrosis. Annals of Oncology, 2012, 23, 276-278.	0.6	16
79	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. European Journal of Cancer, 2020, 137, 117-126.	1.3	16
80	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. Npj Precision Oncology, 2020, 4, 27.	2.3	16
81	Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. Investigational New Drugs, 2010, 28, 529-530.	1.2	15
82	Experience of Gemcitabine plus Oxaliplatin Chemotherapy in Patients with Advanced Biliary Tract Carcinoma. Chemotherapy, 2010, 56, 234-238.	0.8	15
83	Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer. Annals of Oncology, 2012, 23, ix116-ix117.	0.6	15
84	Modifying phase I methodology to facilitate enrolment of molecularly selected patients. European Journal of Cancer, 2013, 49, 1515-1520.	1.3	15
85	An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma. Annals of Oncology, 2017, 28, 2827-2835.	0.6	15
86	Role of image-guided biopsy and radiomics in the age of precision medicine. Chinese Clinical Oncology, 2019, 8, 57-57.	0.4	15
87	Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	15
88	Safety, tolerabilityÂand antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. European Journal of Cancer, 2017, 83, 194-202.	1.3	14
89	Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. Seminars in Oncology, 2017, 44, 114-128.	0.8	14
90	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. European Journal of Cancer, 2018, 92, 1-10.	1.3	14

#	Article	IF	CITATIONS
91	5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy. Anti-Cancer Drugs, 2019, 30, 313-317.	0.7	14
92	Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients. PLoS ONE, 2009, 4, e6483.	1.1	14
93	Peroxisome Proliferator-Activated Receptors in HBV-Related Infection. PPAR Research, 2009, 2009, 1-6.	1.1	12
94	Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma. Cancer Biomarkers, 2015, 15, 151-156.	0.8	12
95	First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. British Journal of Cancer, 2020, 123, 1235-1243.	2.9	12
96	Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunology, Immunotherapy, 2021, 70, 221-232.	2.0	12
97	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget, 2018, 9, 9741-9750.	0.8	12
98	Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. European Journal of Cancer, 2017, 81, 81-89.	1.3	11
99	Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. , 2014, , .		11
100	A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer Journal of Clinical Oncology, 2014, 32, 2620-2620.	0.8	11
101	Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancers, 2022, 14, 406.	1.7	11
102	A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. PLoS ONE, 2016, 11, e0154895.	1.1	10
103	Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Anti-Cancer Drugs, 2017, 28, 341-349.	0.7	10
104	Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. European Journal of Cancer, 2018, 98, 17-22.	1.3	10
105	Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opinion on Investigational Drugs, 2021, 30, 401-409.	1.9	10
106	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>BRAF</i> ^{V600} mutation Journal of Clinical Oncology, 2017, 35, 9074-9074.	0.8	10
107	Clinical activity of <scp>CCâ€90011</scp> , an oral, potent, and reversible <scp>LSD1</scp> inhibitor, in advanced malignancies. Cancer, 2022, 128, 3185-3195.	2.0	10
108	Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. Annals of Oncology, 2016, 27, 344-352.	0.6	9

#	Article	IF	CITATIONS
109	A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients Journal of Clinical Oncology, 2017, 35, 2507-2507.	0.8	9
110	Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study Journal of Clinical Oncology, 2018, 36, 4049-4049.	0.8	9
111	Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test. Cells, 2022, 11, 1901.	1.8	9
112	Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors. Archives of Cardiovascular Diseases, 2018, 111, 285-296.	0.7	8
113	Inclusion of Patients With Advanced Cancer in Phase I Trials: Is This a Tool for Improving Optimism and Emotional Well-Being?. Journal of Clinical Oncology, 2013, 31, 817-818.	0.8	7
114	Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. Investigational New Drugs, 2018, 36, 619-628.	1.2	7
115	Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?. British Journal of Cancer, 2018, 119, 937-939.	2.9	7
116	Development of a score that predicts survival among patients with bone metastasis revealing solid tumor. Supportive Care in Cancer, 2008, 16, 1089-1093.	1.0	6
117	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. Leukemia and Lymphoma, 2018, 59, 1742-1745.	0.6	6
118	Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2. JCO Clinical Cancer Informatics, 2019, 3, 1-10.	1.0	6
119	Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. Cancer Research, 2015, 75, CT139-CT139.	0.4	6
120	Patients aged over 75 years enrolled in Phase I clinical trials: the <scp>G</scp> ustave <scp>R</scp> oussy experience. International Journal of Cancer, 2016, 138, 875-880.	2.3	5
121	Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. BMC Cancer, 2017, 17, 547.	1.1	5
122	Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials. JCO Clinical Cancer Informatics, 2021, 5, 709-718.	1.0	5
123	Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. Cancers, 2021, 13, 3776.	1.7	5
124	First case report of intrathecal panitumumab for treatment of meningeal carcinomatousis in an EGFR mutant lung adenocarcinoma patient. Lung Cancer, 2013, 80, 113-114.	0.9	4
125	Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?. Hepatic Oncology, 2016, 3, 109-118.	4.2	4
126	Are phase I trials safe for older patients?. Journal of Geriatric Oncology, 2018, 9, 87-92.	0.5	4

#	Article	IF	CITATIONS
127	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers Journal of Clinical Oncology, 2018, 36, 4032-4032.	0.8	4
128	MORPHEUS: A phase lb/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer Journal of Clinical Oncology, 2018, 36, TPS4134-TPS4134.	0.8	4
129	Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients. Annals of Oncology, 2016, 27, vi38.	0.6	3
130	Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. Investigational New Drugs, 2017, 35, 79-86.	1.2	3
131	Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Investigational New Drugs, 2018, 36, 62-74.	1.2	3
132	Interventional Radiology for Colorectal Liver Metastases. Current Colorectal Cancer Reports, 2020, 16, 29-37.	1.0	3
133	A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results Journal of Clinical Oncology, 2014, 32, 2506-2506.	0.8	3
134	Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2018, 36, 816-816.	0.8	3
135	Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?. Frontiers in Immunology, 2021, 12, 745146.	2.2	3
136	When Imaging Becomes Clinically Relevant: Multikinase Inhibitor–related Pancreatic Insufficiency and Pancreatic Atrophy. Radiology, 2017, 282, 609-610.	3.6	2
137	Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study. Clinical Colorectal Cancer, 2018, 17, e99-e107.	1.0	2
138	An appraisal of emerging second line therapies for metastatic colorectal cancer. Expert Review of Gastroenterology and Hepatology, 2021, 15, 165-179.	1.4	2
139	Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus. European Journal of Cancer, 2021, 142, 147-149.	1.3	2
140	Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large <scp>B</scp> â€cell lymphoma: Results of <scp>LNHâ€EP1</scp> study. American Journal of Hematology, 2021, 96, E376-E379.	2.0	2
141	Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer Journal of Clinical Oncology, 2014, 32, 2509-2509.	0.8	2
142	A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer Journal of Clinical Oncology, 2017, 35, TPS3626-TPS3626.	0.8	2
143	Evaluation of PFS ratio in patients with cancer enrolled in early-phase clinical trials: A single center, retrospective analysis Journal of Clinical Oncology, 2017, 35, e14025-e14025.	0.8	2
144	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. European Journal of Cancer, 2022, 167, 42-53.	1.3	2

#	Article	IF	CITATIONS
145	Inflammatory vocal fold lesions associated with angiogenesis inhibition. Head and Neck, 2014, 36, n/a-n/a.	0.9	1
146	Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years. European Journal of Cancer, 2021, 156, 217-221.	1.3	1
147	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study Journal of Clinical Oncology, 2017, 35, 2004-2004.	0.8	1
148	Oxaliplatin desensitization after hypersensitivity reaction: A single-center experience on more than 300 procedures Journal of Clinical Oncology, 2018, 36, 610-610.	0.8	1
149	Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials. European Journal of Cancer, 2022, 163, 98-107.	1.3	1
150	Prognostic Factors of Tumour Cellularity in Image-Guided Biopsies: Results from a Prospective Molecular Triage Trial (Moscato). Annals of Oncology, 2014, 25, iv564.	0.6	0
151	Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. International Journal of Cardiology, 2016, 214, 364-369.	0.8	0
152	Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial. Annals of Oncology, 2017, 28, vi55.	0.6	0
153	Abstract B174: Baseline and procedural characteristics influencing tumor cell content on on-purpose tumor biopsies: Results from a prospective molecular triage trial (MOSCATO) , 2013, , .		0
154	Abstract C65: First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors , 2013, , .		0
155	Abstract A130: Joint cell-line (CCLE, Sanger) and patient (TCGA) modeling of drug sensitivity reveals novel molecular biomarkers for targeted therapy and conventional chemotherapy , 2013, , .		0
156	Final results from the phase I study expansion cohort of Debio0932, an oral HSP90 inhibitor, in patients with solid tumors Journal of Clinical Oncology, 2014, 32, 2550-2550.	0.8	0
157	Axitinib in refractory colorectal metastatic cancer: A phase II study of increasing doses with dynamic contrast-enhanced ultrasonography monitory of the response Journal of Clinical Oncology, 2014, 32, 3638-3638.	0.8	0
158	Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy Journal of Clinical Oncology, 2014, 32, 2565-2565.	0.8	0
159	Genomic characterization of metastatic cisplatin-resistant samples from urothelial cancer patients Journal of Clinical Oncology, 2014, 32, 11057-11057.	0.8	0
160	Abstract 900: Computing tumor growth rate across pre- and post-treatment periods uncovers anti-tumor activity in patients treated by a pan-CDK inhibitor (BAY1000394). , 2014, , .		0
161	Genomic landscape of metastatic platin-resistant urothelial cancer patients Journal of Clinical Oncology, 2015, 33, 316-316.	0.8	0
162	Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors Journal of Clinical Oncology, 2015, 33, 2599-2599.	0.8	0

#	Article	IF	CITATIONS
163	Profiles of screen-failures in phase 1 clinical trials Journal of Clinical Oncology, 2015, 33, e17518-e17518.	0.8	0
164	Abstract 2401: Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial. , 2015, , .		0
165	A phase IB, multicenter, open-label study to assess the safety, tolerability, and efficacy of the pleiotropic pathway modifier CC122 administered orally to patients with advanced HCC Journal of Clinical Oncology, 2017, 35, 379-379.	0.8	0
166	Overall survival prognosis of patients in immuno-oncology phase I trials: The Gustave Roussy score Journal of Clinical Oncology, 2017, 35, 3029-3029.	0.8	0
167	MET aberrations across multiple tumor types: Results of a molecular screening program (MOSCATO) Tj ETQq1 1 ().784314 0.8	rgBT /Overlo
168	Abstract 1011: RNAseq analysis obtained from on-purpose tumor biopsies of patients in the MATCH-R trial allows the identification of potential mechanisms of acquired resistance to PD(L)1 therapies. , 2017, , .		0
169	Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers. Cancer Treatment and Research Communications, 2022, 32, 100611.	0.7	0